Overview

A Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Systemic Juvenile Idiopathic Arthritis (SKYPS)

Status:
Recruiting

Trial end date:
2027-04-01

Target enrollment:

Participant gender:

Summary

Primary Objective: To describe the pharmacokinetic (PK) profile of sarilumab in patients aged 1-17 years with Systemic Juvenile Idiopathic Arthritis (sJIA) in order to identify the dose and regimen for adequate treatment of this population. Secondary Objective: To describe the pharmacodynamics (PD) profile, the efficacy, and the long term safety of sarilumab in patients with sJIA.

Phase:

Phase 2

Details

Lead Sponsor:

Sanofi

Collaborator:

Regeneron Pharmaceuticals